SCHEDULE: Capital International Investors Discloses Ascendis Pharma Stake
Beneficial Ownership Filing
Capital International Investors has reported a 3.2% stake in Ascendis Pharma AS, holding 2,013,285 shares as of March 31, 2026.
Summary
- Capital International Investors (CII) has filed a Schedule 13G, indicating beneficial ownership of 2,013,285 shares of Ascendis Pharma AS common stock.
- This holding represents 3.2% of the total class of securities.
- The filing is an amendment (Amendment No. 1) and the event date requiring the filing is March 31, 2026.
- CII has sole voting power over 2,005,343 shares and sole dispositive power over 2,013,285 shares.
- Ascendis Pharma AS's principal executive offices are located in Hellerup, Denmark.
- Capital International Investors is a division of Capital Research and Management Company (CRMC) and its subsidiaries.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about the company.
Positives
- Significant institutional ownership reported by Capital International Investors, indicating confidence in Ascendis Pharma AS.
- The filing confirms a substantial holding of 3.2% of the company's common stock.
Future Outlook
This filing does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates Capital International Investors' position in the biopharmaceutical sector, specifically within Ascendis Pharma AS's shareholder base.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event which requires filing of this statement |
| 05/13/2026 | Date of certification by Capital International Investors |
Keywords
Ascendis Pharma AS, Schedule 13G, Capital International Investors, beneficial ownership, common stock, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.